The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy. i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation
Study Type
OBSERVATIONAL
Enrollment
1,089
Percentage of Participants With Adverse Events, Adverse Drug Reactions, and Serious Adverse Events
The aim of this Post Marketing Surveillance (PMS) was to obtain safety data with treatment of pramipexole in Parkinson's disease patients with depressive symptoms. The percentage of participants with adverse events, adverse drug reactions, and serious adverse events are presented.
Time frame: for 12 weeks
Clinical Global Impression of Improvement
Investigators evaluation of the Parkinson's disease (PD) symptoms on the Clinical Global Impression (CGI) with 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
Time frame: for 12 weeks after initiation of the treatment
Mean Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Part III of the UPDRS contains the clinician-scored motor evaluation, and includes 14 individual items each scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56. A negative change in the Part III total score indicates improvement.
Time frame: Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in Beck's Depression Inventory (BDI) Total Score
The degree of severity in depressive state are scored between 0-63 in BDI. A decrease in the score means improvement.
Time frame: Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I Item 3 Score
Unified Parkinson's Disease Rating Scale Part I Item 3 assesses the participant for symptoms of depression. Item 3 scores range from 0 (None) to 4 (Sustained depression with suicidal thoughts or intent). A higher score indicates more severe depression symptoms. A negative change in the item 3 score indicates improvement.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site
Akashi, Japan
Boehringer Ingelheim Investigational Site 1
Akita, Japan
Boehringer Ingelheim Investigational Site 2
Akita, Japan
Boehringer Ingelheim Investigational Site
Asahikawa, Japan
Boehringer Ingelheim Investigational Site
Ashikaga, Japan
Boehringer Ingelheim Investigational Site
Awaji, Japan
Boehringer Ingelheim Investigational Site
Chitose, Japan
Boehringer Ingelheim Investigational Site
Chūō, Japan
Boehringer Ingelheim Investigational Site 1
Fuchū, Japan
Boehringer Ingelheim Investigational Site 2
Fuchū, Japan
...and 228 more locations
Time frame: Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in Modified Hoehn & Yahr Rating Scale
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden). A negative change in the Yahr rating scale indicates improvement.
Time frame: After 12 weeks or at the time of discontinuation